We break through tumor defenses to enable cancer cures.


A tumor is a fortress whose defenses can block chemotherapies from reaching the cancer cells growing inside. To expose cancer cells to cancer cell killers, the nutritional support structures and protective barriers of tumors must first be destroyed.

CytImmune’s nanotherapy platform, Aurimune, is a tumor-targeted Trojan horse. It is engineered to travel safely and stealthily through the body and enter tumors through their most vulnerable points – the leaky blood vessels that make up the nutritional support structures. Aurimune selectively binds TNF receptors on blood vessel cells at the site of disease. Once bound, Aurimune unleashes a therapeutic payload that destroys the tumor’s nutritional support structures and protective barriers.

This “opens the gate” for cancer cell killers to penetrate the tumor and eradicate disease.

Tumor-Targeted Trojan Horse

  • Aurimune travels through the body by stealth.Read More  
  • Aurimune is highly targeted to tumors.Read More  
  • Aurimune “opens the gate” allowing chemo to work. Read More  
Aliquam pulvinar neque tristique enim rutrum, ac blandit orci dignissim aliquam sed consectetur massa, et tempor tellus quisque vulputate, orci id adipiscing tincidunt, massa tortor luctus lectus, a sodales magna est sit amet urna.
- Dr. John Doe, MD
Montefiore Medical Center


CytImmune created Aurimune to make a quantum leap forward in the technology available to safely and effectively deliver a range of anti-cancer therapies into tumors.

Gold-based nanotechnology

The center of the Aurimune platform is a precisely sized gold nanoparticle. Sizing is optimized to leverage the inherent leakiness of tumor blood vessels. Gold has low toxicity and regulators understand its safety profile since it has been used therapeutically in humans for decades.

PolyEthylene Glycol

PEG is a water-absorbing molecule that covers the gold particle like tiny hairs and is key to the stealthy nature of the Aurimune platform. PEG attracts and holds a protective water shield around the nanotherapy as it passes through the body. This creates the “water shield” that surrounds the nanomedicine.

Tumor Necrosis Factor

TNF breaks down the blood vessel architecture inside tumors. This makes the cancer cells inside the tumor vulnerable to anti-cancer agents.

Proprietary Linkers

CytImmune developed patented linker technology to attach small molecule, anti-cancer agents directly to the Aurimune nanomedicine. These linkers are unique and can be adjusted to work with a variety of agents targeting multiple tumor types.

Optional Cancer-Cell-Killing Agent

Other biological or chemical anti-cancer agents can be added to the core Aurimmune nanomedicine. They can be precisely delivered to kill growing cancer cells inside the tumor.


Clinical Trials


A first generation Aurimune platform nanotherapy, CYT-6091, carries TNF into tumors to disrupt their blood vessels and enable follow-on chemotherapy to penetrate the tumor and kill the cancer cells inside. In a successful Phase I clinical trial, CYT-6091 safely delivered what would have been a toxic but highly effective dose of the anti-cancer agent TNF to patients; dose levels were three times the previous maximum tolerated dose. Tissue samples, taken 24 hours after CYT-6091 administration, showed that the nanomedicine had concentrated inside tumor tissues, not inside surrounding healthy tissue.

A Phase II clinical trial will treat pancreatic cancer patients in combination with standard of care second line therapy. Additional details related to the Phase II trial will be announced.

Preclinical Studies


A second generation Aurimune platform nanomedicine, CYT-21000, carries Taxol (paclitaxel) in addition to TNF. Aurimune is currently the only nanotechnology that has been able to simultaneously deliver a biologic, TNF, and a small molecule therapeutic, Taxol, carried by the same nanoparticle.


AstraZeneca Partnership

CytImmune is currently working with AstraZeneca’s Oncology Innovative Medicines Unit to examine the viability of delivering one or more AstraZeneca anti-cancer therapies into solid tumors using the Aurimune nanomedicine platform.

Other CytImmune Investigations

CytImmune has successfully linked other anti-cancer agents to the Aurimune platform. These include:

  • Interferon (CYT-61000)
  • Gemcitabine (CYT-71000)


The Aurimune nanomedicine platform offers the potential to enable and/or expand the clinical benefit of a variety of toxic anti-cancer therapies -- either as monotherapies or in combination with existing standards of care. Aurimune functions are independent of tumor-specific biochemistry; therefore it does not depend on the type of cancer treated.

However, since cancer is not a single disease, CytImmune has developed a pipeline of Aurimune-based products to attack cancers through different biologic pathways.

CytImmune and the Aurimune platform offer unique advantages including:

- The only clinical stage tumor-targeted product that can carry both biologics and small molecule therapeutics;
- Experience with numerous therapeutic classes of drugs enabling them to bind to the Aurimune platform; and
- A successful track record working with other institutions to integrate existing anti-cancer agents onto the Aurimune nanomedicine, rescuing molecules whose systemic toxicity has stifled clinical development.

CytImmune is open to investigating potential partnerships. For more information, contact Mitchell Marder at (301) 825-3041.



Founded in 1988, CytImmune has transitioned from a successful diagnostics company into a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies.

CytImmune is a global leader in the field of nanomedicine with the successful completion of a Phase I clinical trial of CYT-6091 — the first in a series of products based on the CytImmune’s Aurimune nanomedicine platform. The company has more than 60 issued and pending patents for its colloidal gold nanotechnology in the United States, European Union, Japan and Canada.


Lawrence Tamarkin, Ph.D.
Co-Founder, President & CEO, Chairman of the Board

Mitchell S. Marder
Executive Vice President, Corporate Development and Chief Legal Officer

Gary Rosenfeld
Chief Financial Officer

David Oarr
External and Executive Communications
Press Contact


Neal Cohen
Senior Vice President of External Affairs, NEI

John Holaday, Ph.D.
Executive Chairman of ExoCyte Therapeutics Pte. Ltd.

Ken Itani
Group General Manager, Itanis International, Inc.

Ira Shapiro
President, Ira Shapiro Global Strategies, LLC

Marc Stanley
Former Acting Deputy Director, National Institute of Standards and Technology


Prof. Alexander M.M. Eggermont, M.D./Ph.D
Director General, Cancer Institute Gustave Roussy, Paris France

David G. I. Kingston, Ph.D
Director, Virginia Tech Center for Drug Discovery, VA USA

Steven K. Libutti, M.D., FACS
Director, Rutgers Cancer Institute of New Jersey,
Formerly, Director, Montefiore Einstein Center for Cancer Care, NY USA

Prof. Kouji Matsushima, M.D., Ph.D.
Department of Molecular Preventive Medicine, University of Tokyo, Tokyo, Japan


For additional information on CytImmune or the Aurimune nanomedicine platform, contact us at:

CytImmune Sciences
15010 Broschart Road
Rockville, MD 20850

Visit CtyImmune.blog for our Latest Science and Insights.